Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Abstract

Get full access to this article

View all access options for this article.

References

Daelman

Maitrot

Maarouf

. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012 Nov;18(11):1647–1649

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Khatri

Man

Giovannoni

. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402–409.

O’Connor

Goodman

Kappos

. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858–1865.

Rispens

Vennegoor

Wolbink

. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899–901.

Ifergan

Kebir

Alvarez

. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin. Brain 2011; 134: 3560–3577.